<DOC>
	<DOCNO>NCT00011089</DOCNO>
	<brief_summary>The purpose study make tenofovir disoproxil fumarate ( DF ) available HIV-infected patient fail anti-HIV drug combination , treatment choice available , whose disease may get bad . This study allow patient obtain tenofovir DF approve marketing .</brief_summary>
	<brief_title>Tenofovir Disoproxil Fumarate HIV-Infected Patients Who Have Not Had Success With Other Anti-HIV Drug Combinations</brief_title>
	<detailed_description>Patients receive daily dos tenofovir DF .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Inclusion Criteria Patients may eligible study : Are HIVpositive . Have viral load ( level HIV blood ) least 10,000 copies/ml PCR within previous 2 month . Have CD4 count 100 cells/mm3 low within previous 2 month . Patients CD4 count 100 high 200 cells/mm3 may also eligible opportunistic ( AIDSrelated ) infection within past 90 day . Have fail treatment least 2 protease inhibitor ( PIs ) least 1 PI plus nonnucleoside reverse transcriptase inhibitor ( NNRTI ) . Are able get effective treatment combination currently approve antiHIV drug . Are least 18 year old . Have negative serum pregnancy test . Are willing use barrier method birth control ( male female ) study 30 day take drug . Exclusion Criteria Patients eligible study : Have kidney disease bone disease . Are pregnant breastfeeding . Abuse alcohol drug . Are take , take within 7 day enrol study , adefovir dipivoxil drug may cause kidney problem , include aminoglycoside antibiotic , cidofovir , foscarnet , intravenous ( IV ) amphotericin B , IV pentamidine , IV vancomycin , chemotherapy ( e.g. , cisplatin ) . Have medical condition medication study investigator believe make him/her unsuitable study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2001</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>Disease Progression</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>9- ( 2-phosphonylmethoxypropyl ) adenine</keyword>
</DOC>